Economic evaluations in European reimbursement submission guidelines: current status and comparisons

被引:19
作者
Bracco, Andrea [1 ]
Krol, Marieke [2 ,3 ]
机构
[1] AMGEN Europe GmbH, Zug, Switzerland
[2] Erasmus Univ, Dept Hlth Policy & Management, Rotterdam, Netherlands
[3] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
关键词
health economics; health technology assessment; pharmacoeconomic guidelines; reimbursement; societal perspective; HEALTH TECHNOLOGY-ASSESSMENT; SOCIETAL PERSPECTIVE; RECOMMENDATIONS; HISTORY; FAMILY;
D O I
10.1586/14737167.2013.837766
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This study aimed to review European national health-economic (HE) guidelines and to identify recent developments in guideline recommendations by comparing the findings with those of a review published in 2001. Guidelines were identified by searching websites of the Internal Society for Pharmacoeconomics and Outcomes Research (ISPOR) and government health insurance agencies, and by a literature review. National guidelines showed broad consistency in ranking clinical data sources and choice of comparators for HE analysis, but varied in recommended costs to be included, methods related to cost calculation and discounting. Many European countries have developed or revised national HE guidelines. The recommendations in these guidelines differ in some key aspects, limiting transferability of outcomes of HE evaluations.
引用
收藏
页码:579 / 595
页数:17
相关论文
共 59 条
[1]  
Alban A, 1998, GUIDELINES PREPARATI
[2]   Using economic evaluations to make formulary coverage decisions - So much for guidelines [J].
Anis, AH ;
Gagnon, Y .
PHARMACOECONOMICS, 2000, 18 (01) :55-62
[3]  
[Anonymous], 2000, MAN STAND CLIN EC EV
[4]  
[Anonymous], GUID METH TECHN APPR
[5]  
[Anonymous], 2011, PE GUID WORLD POL
[6]  
[Anonymous], 2010, GUIDELINES EC EVALUA
[7]  
[Anonymous], KCE REPORTS C
[8]  
[Anonymous], 2005, NORW GUID PHARM AN C
[9]  
[Anonymous], 2009, GUID PREP HLTH EC EV
[10]  
[Anonymous], 2008, HLTH TECHN ASS HDB 2